Lung Cancer
Taxotere (docetaxel) and platinum combination provide quality of life advantage as first-line treatment
Published in Cancer Weekly, July 9th, 2002
A chemotherapy regimen that combines Taxotere (docetaxel) for Injection Concentrate with a platinum compound leads to a significantly better quality of life than the combination of vinorelbine (Navelbine) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) who have not undergone prior chemotherapy, according to results of a multinational phase III trial reported at the 38th annual meeting of the American Society of Clinical Oncology (ASCO).
The combination of vinorelbine and cisplatin is a standard first-line regimen in this patient group.
"The data showed that patients who received docetaxel with either cisplatin or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2002-07-09)
More Articles from Cancer Weekly
- Breast Cancer
Strategy of eliminating Stat5a might reduce breast cancer cell survival - Prostate Cancer
Reactive stroma regulates neovascularization in prostate tumors - COX-2
Selective enzyme inhibitor NS-398 arrests the growth of liver cancer cells - Cancer Therapy
Trojan horse drug duo destroys tumors' blood supply - Melanoma
Natural resistance of pigment cells to sunlight may make deadly skin cancer tough to treat - Neuroblastoma
Flavopiridol an angiogenic modulator in tumors affecting children - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
